Definitive Contract W81XWH20C0137
Award Date
9/25/20
Potential Completion Date
9/30/26
Potential Value
$52M
Federal Agency
Defense Health Agency
Ultimate Awardee
Not listed
PSC Category
Q517 - Pharmacy Services
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Fixed Price Level of Effort
Place of Performance
Sweden
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines & Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion date...
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...
<p>This is a cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Janssen Vaccines & Prevention B.V. (JPC), a foreign-owned for-profit organization. The $196,408,488.00 contract does not have a set-aside designation and has an ultimate completion date of March 30, 2026. The contract was awarded on September 28, 2017.</p>
This is a federal contract awarded by the Medical Command division of the U.S. Department of Defense to Emergent Travel Health Inc., a for-profit biopharmaceutical company. The contract, valued at $3,161,941.10, is for a Small Business Innovation Research (SBIR) Phase III action, a non-set-aside contract type. Emergent Travel Health Inc. is providing goods and services related to vaccine stability testing, vaccine development, and vaccine procurement under this definitive, cost-plus-fixed-fee...
<p>This is a $323,554,976.00 Firm Fixed Price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Paratek Pharmaceuticals, Inc. for the development of an antibiotic to treat a biothreat indication. The contract has an ultimate completion date of December 17, 2029 and was awarded on December 18, 2019. This contract is not associated with a set-aside program.</p>
This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to IDT Biologika GMBH, a foreign-owned, for-profit biotechnology company based in Germany. The contract is a $70,108.14 delivery order under a larger indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle for manufacturing and characterization services for vaccines and other biologics for infectious diseases. The...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to IDT Biologika GMBH, a German biotechnology company. The contract, valued at $9,317,000.00, is for the manufacturing of master cell banks for next-generation SARS-CoV-2 vaccines as part of pandemic preparedness efforts. The contract is a delivery order with a firm fixed-price pricing structure and has an ultimate completion...
This firm fixed-price contract, valued at $762,812,695, was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company. The contract is for the development of medical countermeasures (MCM) that can be deployed in the event of a filovirus outbreak, which is a crucial component of the U.S. government's outbreak response...
This federal contract award, valued at $24,295,876.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services. The contract was awarded to IDT Biologika GMBH, a German biotechnology company, to manufacture influenza virus human challenge material for Phase 1 and 2 clinical trials. The contract is a delivery order with a firm fixed price, and has an ultimate completion date of May 14, 2028. No set-aside...
This is a federal contract award from the Defense Health Agency to Entegrion, Inc., a for-profit manufacturing company, with a ceiling value of $18,250,856.31. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type. The contract was awarded on September 28, 2016 with a completion date of September 27, 2021. The contract does not have a set-aside designation. The award is for "FUNDING FOR CLIN 0001" and the place of performance is Research Triangle Park, North...